Elucid
Elucid is harnessing scientific imaging and artificial intelligence to enable quick, accurate, noninvasive diagnoses and precise treatment of cardiovascular disease to enable better patient outcomes. Introducing the first and only non-invasive image analysis software that employs CT angiography and patented computer algorithms, based on expert histologic examination of thousands of tissue samples, to objectively quantify the extent and stability of arterial plaque for tailored patient care. The Elucid Plaque Analysis software is available for commercial use in the U.S., Europe and South Korea.
Company details
Find locations served, office locations
- Business Type:
- Software vendor
- Industry Type:
- Medical / Health Care
- Market Focus:
- Internationally (various countries)
About us
Elucid is a Boston-based medical technology company using AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with known or suspected cardiovascular disease and drive diagnostic precision forward towards truly personalized medicine. The company’s software is the first FDA-cleared & CE-marked non-invasive tool to quantify atherosclerotic plaque against histology, quantify Lipid Rich Necrotic Core, and derive fractional flow reserve based on the vasodilative capacity of the vessel wall. This unique information informs better treatment decisions by physicians and early prediction and prevention of cardiovascular disease leading to better patient outcomes, improved quality of care and reducing overall cost. Elucid’s software is available for commercial use in the U.S. and Europe.